Please email us at [email protected] with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


RX ITEM-AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+

AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+ Details
NDC# 33332-0320-01
Supplier
0050000181 ASD SPEC. HEALTHCARE/DS
RX989418
Supplier Material # 56273
 # 10237209 AFLURIA PRE-FILLED SYRINGES QUADRIVALENT FLU VACCINE 20-21 FOR 65 YEARS AND OLDER RX ITEM-AFLURIA QUAD SY 10X0.5ML 20-21 PF BY SEQUIRIS  FOR ADULT 65 YEARS AND OLDER Item No.:RX3685120 3685120 /M  NDCAFLURIA FLU VACCINE QUAD MD 5ML 19-20 10DS BY SEQUIRIS 2019-2020Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.FLUAD- influenza vaccine, adjuvanted injection, suspensionFLUAD- influenza vaccine, adjuvanted injection, suspension

RX ITEM-AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+

$299.99$239.00

RX ITEM-AFLURIA QUAD SY 10X0.5ML 20-21 PF BY SEQUIRIS FOR 36 MONTHS & OLDER Item No.:RX989418 989418 NDC No.33332-0320-01 33332-320-01 3333232001 33332032001 UPC No.:3-33332-32001-1 333332320011 333332-320011 MPN 32001 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order t RX item.

Have a question?

These highlights do not include all the information needed to use AFLURIA® QUADRIVALENT safely and effectively. See full prescribing information for AFLURIA QUADRIVALENT.

AFLURIA QUADRIVALENT, Influenza Vaccine
Suspension for Intramuscular Injection
2020-2021 Formula
Initial U.S. Approval (AFLURIA QUADRIVALENT): 2016
RECENT MAJOR CHANGES
Dosage and Administration (2) 08/2020
INDICATIONS AND USAGE

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. (1)
AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older. (1)

DOSAGE AND ADMINISTRATION

For intramuscular injection only, by needle and syringe (6 months and older) or by PharmaJet®Stratis® Needle-Free Injection System (18 through 64 years). (2)

a1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines. (2)
Age Dose Schedule
6 months through 35 months One or two dosesa, 0.25 mL each If 2 doses, administer at least 1 month apart
36 months through 8 years One or two dosesa, 0.5 mL each If 2 doses, administer at least 1 month apart
9 years and older One dose, 0.5 mL Not Applicable
DOSAGE FORMS AND STRENGTHS

AFLURIA QUADRIVALENT is a suspension for injection supplied in three presentations:

0.25 mL pre-filled syringe (single dose) (3, 11)
0.5 mL pre-filled syringe (single dose) (3, 11)
5 mL multi-dose vial (0.25 mL or 0.5 mL doses) (3, 11)

CONTRAINDICATIONS

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine. (4, 11)

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks. (5.1)
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine. (5.2)

ADVERSE REACTIONS

AFLURIA QUADRIVALENT administered by needle and syringe:

In adults 18 through 64 years, the most commonly reported injection-site adverse reaction was pain (≥ 40%). The most common systemic adverse events were myalgia and headache (≥ 20%). (6.1)
In adults 65 years of age and older, the most commonly reported injection-site adverse reaction was pain (≥ 20%). The most common systemic adverse event was myalgia (≥ 10%). (6.1)
In children 5 through 8 years, the most commonly reported injection-site adverse reactions were pain (≥ 50%), redness and swelling (≥ 10%). The most common systemic adverse event was headache (≥ 10%). (6.1)
In children 9 through 17 years, the most commonly reported injection-site adverse reactions were pain (≥ 50%), redness and swelling (≥ 10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥ 10%). (6.1)
In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%).The most common systemic adverse events were irritability (≥ 30%), diarrhea and loss of appetite (≥ 20%). (6.1)
In children 36 through 59 months of age, the most commonly reported injection site reactions were pain (≥ 30%) and redness (≥ 20%). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea (≥ 10%). (6.1)

AFLURIA (trivalent formulation) administered by the PharmaJet Stratis Needle-Free Injection System:

In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions were tenderness (≥ 80%), swelling, pain, redness (≥ 60%), itching (≥ 20%) and bruising (≥ 10%). The most common systemic adverse events were myalgia, malaise (≥ 30%), and headache (≥ 20%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
USE IN SPECIFIC POPULATIONS

The safety and effectiveness of AFLURIA QUADRIVALENT in persons less than 6 months of age have not been established. (8.4)
Antibody responses were lower in geriatric subjects than in younger adults. (8.5)
Pregnancy: There is a pregnancy exposure registry that monitors outcomes in women exposed to AFLURIA QUADRIVALENT during pregnancy. Enroll in the pregnancy registry by calling 1-855-358-8966 or sending an email to [email protected] (8.1).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2020

AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+
AFLURIA PFS 60MCG/.5ML QUAD FL
AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+

AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+ Details
NDC# 33332-0320-01
Supplier
0050000181 ASD SPEC. HEALTHCARE/DS
RX989418
Supplier Material # 56273
 # 10237209
AFLURIA PFS 60MCG/.5ML QUAD FL
AFLURIA PFS 60MCG/.5ML QUAD FLU VACCINE 20-21 BY SEQUIRIS 36 MONTHS+ Details NDC# 33332-0320-01 Supplier 0050000181 ASD SPEC. HEALTHCARE/DS RX989418 Supplier Material # 56273 # 10237209

AFLURIA PRE-FILLED SYRINGES QUADRIVALENT FLU VACCINE 20-21 FOR 65 YEARS AND OLDER RX ITEM-AFLURIA QUAD SY 10X0.5ML 20-21 PF BY SEQUIRIS  FOR ADULT 65 YEARS AND OLDER Item No.:RX3685120 3685120 /M  NDC
AFLURIA PRE-FILLED SYRINGES QU
AFLURIA PRE-FILLED SYRINGES QUADRIVALENT FLU VACCINE 20-21 FOR 65 YEARS AND OLDER RX ITEM-AFLURIA QUAD SY 10X0.5ML 20-21 PF BY SEQUIRIS FOR ADULT 65 YEARS AND OLDER Item No.:RX3685120 3685120 /M NDC

AFLURIA FLU VACCINE QUAD MD 5ML 19-20 10DS BY SEQUIRIS 2019-2020
AFLURIA FLU VACCINE QUAD MD 5M
AFLURIA FLU VACCINE QUAD MD 5ML 19-20 10DS BY SEQUIRIS 2019-2020

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at [email protected] prices.

FLUAD- influenza vaccine, adjuvanted injection, suspension
FLUAD- influenza vaccine, adju
FLUAD- influenza vaccine, adjuvanted injection, suspension

FLUAD- influenza vaccine, adjuvanted injection, suspension
FLUAD- influenza vaccine, adju
FLUAD- influenza vaccine, adjuvanted injection, suspension